需要新的生物标志物来指导新的卵巢癌治疗方法，该疾病的标准治疗方法仍然严重依赖基于铂的化疗。尽管PARP抑制剂取得了成功，但治疗选择有限，尤其是在铂耐药的情况下。NaPi2b 是一种细胞表面的、依赖钠的磷酸盐转运蛋白，在正常生理条件下调节磷酸盐代谢平衡，并且是一种细胞谱标记，在选择性癌症中表达，包括卵巢癌、肺癌、甲状腺癌和乳腺癌，而在正常组织中表达有限。基于其在卵巢肿瘤中的高表达，NaPi2b 是一个有前途的候选生物标志物，可以在卵巢癌的治疗和患者选择中进行研究。在临床前研究中，对 NaPi2b 使用的抗体显示出这种蛋白质可被用于肿瘤映射和治疗靶向。在卵巢癌的1期和2期临床试验的新进数据表明，可以使用免疫组织化学方法成功检测患者活检样本中的 NaPi2b，评估中的 NaPi2b 靶向抗体药物结合物似乎引起了治疗反应。本文的目的是审查支持 NaPi2b 作为卵巢癌潜在治疗和患者选择的新型生物标志物的文献，并讨论推动该生物标志物和治疗靶向研究的关键下一步和未来分析。版权 © 2022 Elsevier Ltd. 发表。

Novel biomarkers are needed to direct new treatments for ovarian cancer, a disease for which the standard of care remains heavily focused on platinum-based chemotherapy. Despite the success of PARP inhibitors, treatment options are limited, particularly in the platinum-resistant setting. NaPi2b is a cell surface sodium-dependent phosphate transporter that regulates phosphate homeostasis under normal physiological conditions and is a lineage marker that is expressed in select cancers, including ovarian, lung, thyroid, and breast cancers, with limited expression in normal tissues. Based on its increased expression in ovarian tumors, NaPi2b is a promising candidate to be studied as a biomarker for treatment and patient selection in ovarian cancer. In preclinical studies, the use of antibodies against NaPi2b showed that this protein can be exploited for tumor mapping and therapeutic targeting. Emerging data from phase 1 and 2 clinical trials in ovarian cancer have suggested that NaPi2b can be successfully detected in patient biopsy samples using immunohistochemistry, and the NaPi2b-targeting antibody-drug conjugate under evaluation appeared to elicit therapeutic responses. The aim of this review is to examine literature supporting NaPi2b as a novel biomarker for potential treatment and patient selection in ovarian cancer and to discuss the critical next steps and future analyses necessary to drive the study of this biomarker and therapeutic targeting forward.Copyright © 2022. Published by Elsevier Ltd.